论文部分内容阅读
1例49岁男性患者因霍奇金淋巴瘤先后行一线和二线化疗方案治疗7个月，肿瘤控制欠佳，改用信迪利单抗200 mg静脉滴注，1次/21 d。治疗前患者肝功能正常。给予信迪利单抗第2次治疗后（首次用药后第42天）患者出现胸闷、腹胀、纳差等症状。复查肝功能：丙氨酸转氨酶（ALT）1 590 U/L，天冬氨酸转氨酶（AST）3 678 U/L，碱性磷酸酶（ALP）468 U/L，γ-谷氨酰转移酶（γ-GT）399 U/L，总胆红素（TBil）50.1 μmol/L，直接胆红素（DBil）26.8 μmol/L。停用信迪利单抗，但患者黄疸加深。给予甲泼尼龙150 mg静脉滴注、1次/d治疗3 d，胆红素达峰值（TBil 152.6 μmol/L，DBil 109.2 μmol/L）。加用吗替麦考酚酯0.5 g口服、2次/d，患者症状逐渐好转，肝功能逐渐恢复。甲泼尼龙联合吗替麦考酚酯治疗6 d后，ALT 63 U/L，AST 78 U/L，TBil 25.2 μmol/L，DBil 12.9 μmol/L；22 d后复查肝功能恢复正常。“,”A 49-year-old male patient was treated with first-line and second-line chemotherapy regimens successively for 7 months because of Hodgkin′s lymphoma. However, the tumor failed to be well controlled. His treatment was changed to intravenous infusion of sintilimab 200 mg once every 21 days. His liver function was normal before treatment. After the second administration of sintilimab (on day 42 after the first medication), the patient developed chest distress, abdominal distension, poor appetite, and etc. Reexamination of liver function showed alanine aminotransferase (ALT) 1 590 U/L, aspartate aminotransferase (AST) 3 678 U/L, alkaline phosphatase (ALP) 468 U/L, gamma-glutamyl transferase (γ-GT) 399 U/L, total bilirubin (TBil) 50.1 μmol/L, and direct bilirubin (DBil) 26.8 μmol/L. Sintilimab was discontinued, but the patient′s jaundice was deteriorated. Intravenous infusion of methylprednisolone 150 mg once daily was given for 3 days, but the bilirubin reached the peak (TBil 152.6 μmol/L, DBil 109.2 μmol/L). Oral mycophenolate mofetil 0.5 g twice daily was added, the patient′s symptoms were gradually improved, and his liver function gradually recovered. After 6 days of combination use of methylprednisolone and mycophenolate mofetil, the laboratory tests showed ALT 63 U/L, AST 78 U/L, TBil 25.2 μmol/L, and DBil 12.9 μmol/L. Twenty-two dags later, his liver function returned to normal.